Skip to main content
Log in

Burden of Disease: Psoriasis and Psoriatic Arthritis

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Psoriatic arthritis (PsA) increases the disease burden associated with psoriasis by further diminishing quality of life, increasing health care costs and cardiovascular risk, and potentially causing progressive joint damage. The presence of PsA influences psoriasis treatment by increasing overall disease complexity and, within the framework of current guidelines and recommendations, requiring the use of conventional disease-modifying anti-rheumatic drugs or tumor necrosis factor-α inhibitors in order to prevent progressive joint damage. Despite its important impact, PsA is still under-diagnosed in dermatology practice. Dermatologists are well positioned to recognize and treat PsA, given that it characteristically presents, on average, 10 years subsequent to the appearance of skin symptoms. Regular screening of psoriasis patients for early evident joint symptoms should be incorporated into daily dermatologic practice. Although drugs effective in PsA are available, not all patients may respond to treatment, and others may lose their initial response over time. New investigational therapies, such as inhibitors of interleukin-17A, interleukin-12/23, Janus kinase 3, or phosphodiesterase-4, may address unmet needs in psoriatic disease, with further research needed to determine the role of these agents in reducing joint damage and other comorbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Prey S, Paul C, Bronsard V, et al. Assessment of the risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl. 2):31–5.

    Article  PubMed  Google Scholar 

  2. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–64.

    Article  PubMed  Google Scholar 

  3. Lloyd P, Ryan C, Menter A. Psoriatic arthritis: an update. Arthritis. 2012;2012:176298.

    Article  PubMed  Google Scholar 

  4. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002;82:108–13.

    Article  PubMed  Google Scholar 

  5. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160:1040–7.

    Article  PubMed  CAS  Google Scholar 

  6. Haroon M, Kirby B, Fitzgerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736-40

    Google Scholar 

  7. Lynde CW, Poulin Y, Guenther L, Jackson C. The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey. J Cutan Med Surg. 2009;13:235–52.

    PubMed  Google Scholar 

  8. Laws P, Barton A, Warren RB. Psoriatic arthritis–what the dermatologist needs to know. J Eur Acad Dermatol Venereol. 2010;24:1270–7.

    Article  PubMed  CAS  Google Scholar 

  9. Yamamoto T. Psoriatic arthritis: from a dermatological perspective. Eur J Dermatol. 2011;21:660–6.

    PubMed  CAS  Google Scholar 

  10. Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704–8.

    Article  PubMed  Google Scholar 

  11. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45:151–8.

    Article  PubMed  CAS  Google Scholar 

  12. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 2011;63(Suppl. 11):S64–85.

    Article  Google Scholar 

  13. Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548–54.

    Article  PubMed  CAS  Google Scholar 

  14. Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology. 2012;51:571–6.

    Article  PubMed  Google Scholar 

  15. McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004;63:162–9.

    Article  PubMed  CAS  Google Scholar 

  16. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59:772–80.

    Article  PubMed  Google Scholar 

  17. Poole CD, Lebmeier M, Ara R, et al. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology. 2010;49:1949–56.

    Article  PubMed  Google Scholar 

  18. Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care. 2002;8(Suppl. 21):S664–81.

    PubMed  Google Scholar 

  19. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. Pharm Ther. 2010;35:680–9.

    Google Scholar 

  20. Kimball AB, Guérin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25:157–63.

    Article  PubMed  CAS  Google Scholar 

  21. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270:147–57.

    Article  PubMed  CAS  Google Scholar 

  22. Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67:76–85.

    Article  PubMed  Google Scholar 

  23. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2012;72:211–6.

    Article  PubMed  Google Scholar 

  24. Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care. 2011;63:1729–35.

    Article  Google Scholar 

  25. Eder L, Jayakar J, Shanmugarajah S, et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis. 2012 (Epub ahead of print).

  26. Boehncke WH, Boehncke S, Tobin A-M, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303–7.

    Article  PubMed  Google Scholar 

  27. Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012;14:343–8.

    Article  PubMed  Google Scholar 

  28. Boehncke WH. Epidemiology and potential pathomechanisms of cardiovascular comorbidities in psoriasis: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39:441–4.

    Article  PubMed  Google Scholar 

  29. Kourosh AS, Miner A, Menter A. Psoriasis as the marker of underlying systemic disease. Skin Therapy Lett. 2008;13:1–5.

    PubMed  CAS  Google Scholar 

  30. Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology. 2010;49:1399–405.

    Article  PubMed  CAS  Google Scholar 

  31. Binus AM, Han J, Qamar AA, et al. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol. 2012;26:644–50.

    Article  PubMed  CAS  Google Scholar 

  32. Scarpa R. New insights into the concept of psoriatic disease. J Rheumatol Suppl. 2012;89:4–6.

    Article  PubMed  Google Scholar 

  33. Boehncke WH, Fichtlscherer S, Salgo R, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res. 2011;303:381–8.

    Article  PubMed  CAS  Google Scholar 

  34. Boehncke WH, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2011;25:1187–93.

    Article  PubMed  CAS  Google Scholar 

  35. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244–50.

    Article  PubMed  CAS  Google Scholar 

  36. Di Minno MN, Iervolino S, Peluso R, on behalf of the CaRRDs study group, et al. Carotid intima-media thickness in psoriatic arthritis. Differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011;31:705–12.

    Article  PubMed  Google Scholar 

  37. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22:40–55.

    Article  PubMed  Google Scholar 

  38. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(Suppl. 1):i77–84.

    Article  PubMed  Google Scholar 

  39. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193:300–3.

    Article  PubMed  Google Scholar 

  40. Wittkowski KM, Leonardi C, Gottlieb A, et al. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One. 2011;6:e20279.

    Article  PubMed  CAS  Google Scholar 

  41. Taylor W, Gladman D, Helliwell P, CASPAR Study Group, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.

    Article  PubMed  Google Scholar 

  42. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology. 2003;42:778–83.

    Article  PubMed  CAS  Google Scholar 

  43. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiologic damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis. 2007;66:370–6.

    Article  PubMed  Google Scholar 

  44. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA): an analysis of 220 patients. Q J Med. 1987;62:127–41.

    PubMed  CAS  Google Scholar 

  45. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991;30:245–50.

    Article  PubMed  CAS  Google Scholar 

  46. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology. 2003;42:1460–8.

    Article  PubMed  CAS  Google Scholar 

  47. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.

    Article  PubMed  Google Scholar 

  48. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl. 2):1–70.

    Article  PubMed  Google Scholar 

  49. Papp K, Gulliver W, Lynde C, Canadian Psoriasis Guidelines Committee, et al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15:210–9.

    PubMed  Google Scholar 

  50. Ritchlin CT, Kavanaugh A, Gladman DD, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387–94.

    Article  PubMed  CAS  Google Scholar 

  51. Gossec L, Smolen JS, Gaujoux-Viala C, European League Against Rheumatism, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4–12.

    Article  PubMed  CAS  Google Scholar 

  52. Augustin M, Glaeske G, Schäfer I, et al. Processes of psoriasis health care in Germany: long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges. 2012;10:648–55.

    PubMed  Google Scholar 

  53. Association of American Medical Colleges. 2008 physician specialty data. Center for Workforce Studies [online]. https://www.aamc.org/download/47352/data/specialtydata.pdf. (Accessed 24 Sep 2012).

  54. Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease. Ann Rheum Dis. 2011;70:2152–4.

    Article  PubMed  Google Scholar 

  55. Iervolino S, Di Minno MN, Peluso R, et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol. 2012;39:568–73.

    Article  PubMed  Google Scholar 

  56. Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutic approach in early psoriatic arthritis: results of a pilot randomized 6-month trial with methotrexate. Clin Rheumatol. 2008;27:823–6.

    Article  PubMed  Google Scholar 

  57. Taylor SL, Petrie M, O’Rourke KS, Feldman SR. Rheumatologists’ recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients’ joint symptoms. J Dermatol Treat. 2009;20:350–3.

    Article  CAS  Google Scholar 

  58. Dominguez P, Husni ME, Garg A, Quershi AA. Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire and the role of dermatologists: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38:548–50.

    Article  PubMed  Google Scholar 

  59. Gladman DD, Schentag CT, Tom BD, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009;68:497–501.

    Article  PubMed  CAS  Google Scholar 

  60. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–72.

    Article  PubMed  CAS  Google Scholar 

  61. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038–43.

    Article  PubMed  CAS  Google Scholar 

  62. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systemic literature review. Rheumatology. 2011;50:518–31.

    Article  PubMed  CAS  Google Scholar 

  63. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2012;273:197–204.

    Article  PubMed  Google Scholar 

  64. Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186:1495–502.

    Article  PubMed  CAS  Google Scholar 

  65. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490–500.

    Article  PubMed  CAS  Google Scholar 

  66. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–11.

    Article  PubMed  CAS  Google Scholar 

  67. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1092–102.

    PubMed  CAS  Google Scholar 

  68. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58:2307–17.

    Article  PubMed  Google Scholar 

  69. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359:419–29.

    Article  PubMed  CAS  Google Scholar 

  70. van Baarsen LG, Lebre MC, van der Coelen D, et al. Expression levels of IL-17A, IL-17F and their receptors in synovium of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis: a target validation study [abstract]. Ann Rheum Dis. 2011;70(Suppl. 3):536.

    Google Scholar 

  71. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondyloarthritis. Arthritis Rheum. 2012;64:99–109.

    Article  PubMed  CAS  Google Scholar 

  72. Hwang SY, Kim JY, Kim KW, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004;6:R120–8.

    Article  PubMed  CAS  Google Scholar 

  73. Adamopoulos IE, Chao CC, Geissler R, et al. Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther. 2010;12:R29.

    Article  PubMed  Google Scholar 

  74. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535–45.

    Article  PubMed  Google Scholar 

  75. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–40.

    Article  PubMed  CAS  Google Scholar 

  76. Mease PJ, Gladman DD, Ritchlin CT, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–89.

    Article  PubMed  CAS  Google Scholar 

  77. Antoni C, Krueger GG, de Vlam K, IMPACT 2 Trial Investigators, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–7.

    Article  PubMed  CAS  Google Scholar 

  78. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study [abstract]. Ann Rheum Dis. 2012;71 Suppl. 3:107 (Abstract OP0158).

  79. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412–21.

    Article  PubMed  CAS  Google Scholar 

  80. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–9.

    Article  PubMed  CAS  Google Scholar 

  81. Papp K, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–9.

    Article  PubMed  CAS  Google Scholar 

  82. McInnes I, Sieper J, Braun J, et al. Anti-interleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial [abstract]. Arthritis Rheum. 2011;63(10 Suppl.):S306.

    Google Scholar 

  83. Marder W, Khalatbari S, Myles JD, et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1550–5.

    Article  PubMed  CAS  Google Scholar 

  84. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306:864–71.

    Article  PubMed  CAS  Google Scholar 

  85. Bigby M. The use of anti-interleukin-12/23 agents and major adverse cardiovascular events. Arch Dermatol. 2012;148:753–4.

    Article  PubMed  Google Scholar 

  86. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27:622–7.

    Article  PubMed  CAS  Google Scholar 

  87. Reich K, Papp KA, Griffiths CEM, PHOENIX 1, PHOENIX 2, and ACCEPT Investigators, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11:300–12.

    PubMed  CAS  Google Scholar 

  88. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–43.

    Article  PubMed  CAS  Google Scholar 

  89. Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 2009;183:2183–92.

    Article  PubMed  CAS  Google Scholar 

  90. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842–55.

    Article  PubMed  CAS  Google Scholar 

  91. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668–77.

    Article  PubMed  CAS  Google Scholar 

  92. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738–46.

    Article  PubMed  CAS  Google Scholar 

  93. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156–67.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Novartis supported this manuscript with an unrestricted writing grant.

Dr Boehncke reports having received honoraria as an advisor or speaker for Abbott, Amgen, Biogen Idec, Janssen, Lilly, MSD, Novartis, and Pfizer and research grants from Janssen and Pfizer. Dr Menter reports having received honoraria as an advisor, investigator, or speaker for Abbott, Allergan, Amgen, Celgene, Galderma, Janssen, LEO Pharma, Lilly, Novartis, Novo Nordisk, Pfizer, Stiefel Laboratories, Syntrix Biosystems, and Wyeth; and research grants from Abbott, Allergan, Amgen, Celgene, Janssen, Lilly, Novartis, Novo Nordisk, Pfizer, Stiefel Laboratories, and Syntrix Biosystems.

Drs Boehncke and Menter had full access to all papers cited in this article and take responsibility for the accuracy of the data analysis. Both authors were responsible for the analysis and interpretation of data reported in this article and in revising the manuscript for important intellectual content. Both approved the final submitted version.

The authors are indebted to Kathryn Miles and Andrew Horgan of BioScience Communications, New York, NY, for help in literature searches and in preparing the draft of this manuscript, activities that were supported by Novartis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wolf-Henning Boehncke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boehncke, WH., Menter, A. Burden of Disease: Psoriasis and Psoriatic Arthritis. Am J Clin Dermatol 14, 377–388 (2013). https://doi.org/10.1007/s40257-013-0032-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-013-0032-x

Keywords

Navigation